

1 **A Differential DNA Methylation Signature of Pulmonary Immune Cells**
2 **from Individuals Converting to Latent Tuberculosis Infection**

3

4 Lovisa Karlsson^{∂1}, Jyotirmoy Das^{∂1}, Moa Nilsson¹, Amanda Tyrén¹, Isabelle Pehrson¹, Nina
5 Idh¹, Jakob Paues^{1,2}, Cesar Ugarte-Gil³, Melissa Méndez-Aranda^{•4}, and Maria Lerm^{•*1}

6

7 ¹Division of Inflammation and Infection, ²Division of Infectious Diseases, Department of
8 Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences, Linköping
9 University, SE-58185, Linköping, Sweden, ³Facultad de Medicina, Instituto de Medicina
10 Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru,
11 ⁴Facultad de Ciencias y Filosofía, Laboratorio de Investigación en Enfermedades Infecciosas,
12 Universidad Peruana Cayetano Heredia, Lima, Peru

13

14

15 *∂) Shared first authorship*

16 *•) Shared last authorship*

17 **) Corresponding author:*

18

19 Maria Lerm, Div. of Inflammation and Infection, Lab 1, floor 12

20 Dept. of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences

21 Linköping University, SE-58185 Linköping, Sweden

22 Phone: +46-732707786, E-mail: maria.lerm@liu.se

23

24

25 **Keywords:** DNA methylation, transcriptome, tuberculosis, BCG, induced sputum,

26 epigenetics, IGRA

27

28 **Abstract**

29 Tuberculosis (TB), caused by *Mycobacterium tuberculosis*, spreads via aerosols and the first
30 encounter with the immune system is with the pulmonary resident immune cells. The role of
31 epigenetic regulations through DNA methylation in the immune cells is emerging. We have
32 previously shown that capacity to kill *M. tuberculosis* is reflected in the DNA methylome.
33 The aim of this study was to investigate epigenetic modifications in the pulmonary immune
34 cells in a cohort of medical students with a previously documented increased risk of TB
35 exposure, longitudinally. Sputum samples containing alveolar macrophages (AMs) and T
36 cells were collected before and after study subjects worked in hospital departments with a
37 high-risk of TB exposure. DNA methylome analysis revealed that a unique DNA methylation
38 profile was present already at inclusion in subjects who developed latent TB during the study.
39 The profile was both reflected in different overall DNA methylation distribution as well as
40 more profound alterations in the methylation status of a unique set of CpG-sites. Over-
41 representation analysis of the DMGs showed enrichment in pathways related to metabolic
42 reprogramming of macrophages and T cell migration and IFN- γ production. In conclusion, we
43 identified a unique DNA methylation signature in individuals, while still IGRA-negative and
44 who later developed latent TB. Epigenetic regulation was found in pathways that have
45 previously been reported to be important in TB. Together the study suggests that DNA
46 methylation status of pulmonary immune cells can predict IGRA conversion.

47

48

49 **Introduction**

50 Tuberculosis (TB) is a major global health concern, ranked as one of the top 10 causes of
51 death worldwide and estimated to be responsible for 1.2 million deaths per year ¹. TB is
52 caused by the facultative intracellular bacteria *Mycobacterium tuberculosis* and one-fourth of
53 the world's population is estimated to be infected making *M. tuberculosis* is one of the most
54 successful pathogens known. *M. tuberculosis* is air-borne and enters the lung where the
55 bacteria are internalized by alveolar macrophages (AMs) through phagocytosis. The
56 “checkpoint model” can be used to describe the following immunological events post
57 infection ^{2,3}. At the first checkpoint, to establish an infection, *M. tuberculosis* needs to evade
58 elimination by AMs. *M. tuberculosis* has developed several strategies to manipulate the host
59 immune response to extend its survival in the phagocytes. The pathogen can arrest maturation
60 of the phagolysosome and direct phagocytes to necrosis, which is prerequisite for the
61 bacterium to spread. In some individuals, referred to as *early clearers*, the pathogen is
62 successfully cleared by innate immune mechanisms at this initial stage of infection ⁴⁻⁶. If the
63 pathogen is replicating and cannot be cleared by the innate immune system, the second
64 checkpoint is reached; activation of the adaptive immune system. When the infection is
65 controlled by the adaptive immune system, asymptomatic latent TB infection (LTBI) has
66 developed. From this point, there is a 5-10% lifetime risk of progression to active TB (ATB),
67 as a result of inadequate immune control, which is the third checkpoint for *M. tuberculosis* ⁷⁻
68 ¹⁰. The Interferon-Gamma Release Assay (IGRA) is an immunological test used to confirm
69 whether a person has been exposed to *M. tuberculosis* based on peripheral T cell release of
70 interferon- γ (IFN- γ) in response to *M. tuberculosis* antigens ¹¹. Another method to confirm
71 exposure is the purified protein derivative (PPD) or Tuberculin skin test, where PPD-antigen

72 is injected intradermally to the forearm and the skin reaction, based on T cell-mediated
73 delayed hypersensitivity response against the antigen, is measured ¹².

74 The role of epigenetics in TB immune responses is emerging. Several studies have described
75 the concept of developing trained immunity through epigenetic reprogramming, leading to
76 proper orchestration of gene expression upon re-exposure to a pathogen or pathogen-derived
77 products ^{3,13,14}. DNA methylation, histone modifications, and regulation of small RNAs are
78 considered as the important players in the regulation of epigenetic modifications ¹⁵. DNA
79 methylations in CpG-rich promotor regions are generally associated with gene silencing ¹⁶.
80 We and others have described the reprogramming of DNA methylation patterns in peripheral
81 blood mononuclear cells (PBMCs) after exposure to live attenuated *Mycobacterium bovis*
82 through the *Bacillus Calmette Guérin* (BCG) vaccination ^{17,18}. Further, we have demonstrated
83 that differences in these DNA methylation patterns affect the efficacy of the macrophages to
84 kill *M. tuberculosis in vitro* ¹⁹. A wealth of literature focus on adaptive immune responses in
85 peripheral blood, but since *M. tuberculosis* primarily infects the lung, it would be more
86 relevant to address pulmonary immunity, including alveolar T cells and AMs ^{20,21}.

87

88 Here, we have increased our focus on the pulmonary-resident immune cells and further
89 investigated DNA methylomes of AMs and alveolar T cells in a cohort of medical students
90 with a previously reported increased risk of *M. tuberculosis* exposure ²². The aim of the study
91 was to investigate epigenetic modifications in the pulmonary immune pre- and post- TB
92 exposure in a natural setting. We hypothesized that this recent exposure to *M. tuberculosis* in
93 the lung compartment would induce epigenetic alterations in AMs and alveolar T cells. By
94 sputum induction AMs and alveolar T cells were isolated ²³. Using reduced representation of
95 bisulfite sequencing (RRBS) the DNA methylome was investigated and we identified a
96 different global DNA methylation profile in pulmonary immune cells of the study subjects

97 that developed latent TB infection during the study. Notably, this global DNA methylation
98 profile was identified in the immune cells already before a latent TB infection could be
99 detected with the IGRA test.

100

101 **Results**

102 *Study design and cohort*

103 Medical students were invited to participate in the study and donated sputum samples before
104 (referred here as 0 months) and after (referred here as 6 months) clinical rotations in
105 departments with a high-risk of *M. tuberculosis* exposure. A schematic overview of the study
106 design is represented in Figure 1. Demographic information of the study subjects and IGRA
107 results are shown in Table 1. One study subject was borderline IGRA-positive²⁴ (IGRA_{pos})
108 already at inclusion (0 months) (Table S1). Two study subjects developed latent TB infection
109 during the study as demonstrated with a positive IGRA test at follow-up (6 months, referred
110 to as IGRA converters in the following text) (Table S1).

111

112 *DNA methylation patterns in alveolar macrophages and T cells before and after TB* 113 *exposure distinguish IGRA converters*

114 To investigate the epigenetic changes in the pulmonary immune cells over time, we isolated
115 DNA from the AMs and alveolar T cells collected at 0 and 6 months and performed Genome-
116 wide Reduced Representation Bisulfite sequencing (RRBS). After filtering the data as
117 described in the method section, we identified a total of 1186 CpG-sites with ≥ 5 reads in the
118 19 samples from the AMs and 404 CpG-sites in the 19 samples from the alveolar T cells. To
119 get an overview of the global DNA methylation distribution in the pulmonary immune cells,
120 we made density plots of the M-values (the \log_2 ratio of the intensities of methylated versus
121 unmethylated CpG-sites) obtained from CpG-sites in the AMs (1186 CpG-sites) and the

122 alveolar T cells (404 CpG-sites), shown in Figure 2A,B. The density plot showed a
123 homogenous distribution of DNA methylation in all samples from the IGRA_{neg} study subjects
124 collected at both at 0 and 6 months. The sample from one study subject, that was IGRA_{pos} at
125 inclusion, followed the same global DNA methylation distribution. Whereas in the IGRA-
126 converting study subjects, we identified a different global DNA methylation profile with more
127 hyper- and hypomethylated CpG-sites as well as different peak densities. Notably, the sample
128 collected at 6 months (after IGRA conversion) displayed a similar DNA methylation profile
129 as the sample collected at inclusion.

130 The results coincided in both the AMs and the alveolar T cells. To further explore the data, we
131 performed a principal component analysis (PCA) which revealed a distinct group formation
132 from the IGRA converters (based on the PC1 (Dim1) with 70% C.I.), including both the
133 samples collected before and after the IGRA conversion (Figure 2C,D). The IGRA_{pos}
134 individual on the other hand clustered with the data obtained from IGRA_{neg} study subjects. We
135 proceeded with a hierarchical clustering analysis by applying the Euclidean
136 similarity/dissimilarity matrix calculation using the M-value (Figure 3A,B). In line with the
137 PCA results, the data from the IGRA converters formed a separate cluster, including both the
138 sample collected before and after IGRA conversion. The same cluster separation was found in
139 both the samples from the AMs and from the alveolar T cells. To visualize the methylation
140 status in the 1186 and 404 CpG-sites from the AMs and T cells respectively, we created
141 heatmaps (Figure 4A,B), demonstrating a clear difference in the overall methylation between
142 IGRA converters and IGRA_{neg} study subjects.

143

144 ***High number of strong DMCs identified in IGRA-converting individuals***

145 To further explore the epigenetic reprogramming that occurred between the two time points, 0
146 and 6 months, we identified the differentially methylated CpG-sites (DMCs) with the strict

147 filtering criteria ($|\log_2 \text{Fold Change} (\log_2 \text{FC})| > 5$ and Benjamini-Hochberg (BH) corrected p -
148 value < 0.01) in each study subject. The DMCs were divided into three different cutoff
149 levels: $|\log_2 \text{FC}|$ 10, 13 and 15 hyper- or hypomethylation in order to understand the
150 distribution of DMCs based on the level of change (Figure 5A,B). A high number of DMCs
151 with a $|\log_2 \text{FC}| > 15$ was identified in the IGRA converters, in both cell types. To normalize
152 the results to account for the different number of total DMCs ($|\log_2 \text{FC}| > 5$, BH adj. p -value $<$
153 0.01) identified we looked at the percentage of DMCs with a $|\log_2 \text{FC}| > 15$ (Figure 5C).

154

155 ***IGRA-converting individuals undergo similar epigenetic changes in DNA methylation***

156 The DMCs were annotated to the official Gene Symbols further analysis and is referred to as
157 DMGs in the following text. To identify the overlap in the DMGs with a $|\log_2 \text{FC}| > 15$
158 between the study subjects, a Venn analysis was performed and presented in an UpSet plot.
159 The IGRA converters shared the largest intersection in both cell types, 452 DMGs in the AMs
160 (Figure 6A) and 471 DMGs in the T cells (Figure S1). 32 DMGs overlapped between the
161 AMs and T cells. To filter out unspecific changes we selected the DMGs that changed in the
162 same direction in both IGRA converters. We identified 280 (128 DMGs were
163 hypermethylated and 152 hypomethylated) and 281 (159 DMGs were hypermethylated and
164 122 hypomethylated) DMGs that became hypo- or hypermethylated, in both IGRA converters
165 in the AMs and in the T cells respectively.

166

167 ***IGRA converters' DMGs are over-represented in pathways related to metabolic 168 reprogramming, T cell migration and IFN- γ production.***

169 In an over-representation analysis (ORA)²⁵ using the PANTHER database²⁶ the identified
170 DMGs from the AMs unique to the IGRA converters were shown to be overrepresented in the
171 Pentose phosphate pathway and the Ras pathway (Table 2). In the ORA of the DMGs from

172 the T cells unique to the IGRA converters we identified muscarinic acetylcholine receptors 1-
173 4 pathway and β 1- and β 2 adrenergic receptor signaling pathway (Table 3).

174

175 **Discussion**

176 In this study we investigated the genome-wide DNA methylation in the pulmonary immune
177 cells in individuals at high risk of exposure to *M. tuberculosis*. DNA methylation has been
178 shown to play an important role in the innate immune systems response to mycobacteria by us
179 and others ^{17,27-30}, however, it has not yet been longitudinally studied in healthy individuals at
180 risk of TB exposure. Two of the study subjects in this study developed latent TB in the course
181 of sample collection as demonstrated by IGRA conversion and our analyses identified a
182 distinct genome-wide DNA methylation profile separating these two individuals from those
183 who remained IGRA_{neg} throughout the study. This DNA methylation profile, which, contrary
184 to our expectation, was present already at inclusion, was characterized by more hypo- and
185 hypermethylated CpG-sites. Intriguingly, the subject diagnosed with latent TB at inclusion,
186 did not cluster with the IGRA converters. From these observations, we propose the following
187 hypotheses: i) the IGRA converters were exposed to TB via the airways already before
188 inclusion and the exposure had not yet developed into circulating T cell memory (resulting in
189 a negative IGRA test) but had caused reprogramming of the DNA methylome of AMs; ii) a
190 different, *inherent* genomic DNA methylation profile as observed in the IGRA converters
191 predispose for IGRA conversion in a high-endemic setting.

192 According the first hypothesis, the observed DNA methylation pattern represents a normal,
193 protective response to TB exposure (as part of the first ‘checkpoint’), which however was
194 breached by the infection and therefore urged the host to induce an adaptive immune response
195 (the second ‘checkpoint’) ^{2,3}. If the second hypothesis applies, a limited capacity for inducing
196 a host-protective epigenetic reprogramming could cause susceptibility and predisposition for

197 latent TB infections. There is a large heterogeneity in the human susceptibility to develop
198 latent or active TB upon exposure and there is limited knowledge in the determining factors
199 ³¹, but larger studies could investigate the correlation between DNA methylation patterns and
200 TB susceptibility. Alternatively, the distinct DNA methylation pattern observed could also be
201 affected by *M. tuberculosis* manipulating the host cells epigenome ^{28,32,33}.

202 The two IGRA converters underwent similar epigenetic changes between the timepoints,
203 during conversion to IGRA positivity. There was a large overlap in DMGs in the IGRA
204 converters in both cell types. The DMG intersect unique to the IGRA converters AMs showed
205 over-representation in the pentose phosphate pathway which has previously been described to
206 be critical in *M. tuberculosis* infected macrophages ^{34,35}. Infected macrophages become
207 dependent on both glycolysis and the pentose phosphate pathway to fulfill the metabolic and
208 bioenergetic requirements for production of cytokines, chemokines and reactive oxygen
209 species (ROS) ³⁴⁻³⁶. The DMGs unique to the IGRA converters' T cells showed over-
210 representation in the pathway for β -adrenergic and muscarinic acetylcholine receptor
211 signaling. A functional role between β 2 adrenergic receptor (β 2AR) activation and IFN- γ and
212 Tumor necrosis factor (TNF) production in T helper 1 (Th1) cells have been established in
213 several studies, activation of β 2AR by the neurotransmitter norepinephrine (NE) decreases the
214 Th1 cells IFN- γ expression ³⁷⁻⁴⁰. Polymorphisms in the β 2AR have also been reported to be
215 associated with TB ⁴¹. The cholinergic system also has a functional role in the T cells. T cells
216 express both muscarinic and nicotinic acetylcholine (ACh) receptors and expression of the
217 enzyme choline acetyltransferase (ChAT) is induced in T cells during infection, T cell derived
218 ACh is involved in T cells migration to tissues ⁴²⁻⁴⁴.

219 One study subject was borderline IGRA positive at inclusion and this subject followed the
220 same DNA methylation distribution and was clustering with the IGRA_{neg} study subjects. The
221 kinetics of the IFN- γ -reaction in relation to point of infection is not elucidated and after TB

222 treatment the peripheral T cell memory will persist for up to 15 months^{45,46}. According to our
223 analysis, the epigenome of the pulmonary immune cells in this individual was more similar to
224 that of healthy individuals and this suggests the possibility that this individual became IGRA
225 positive a long time ago and that the epigenome profile in the pulmonary immune cells has
226 returned to baseline.

227

228 If the DNA methylation profile observed in the IGRA converters is an early result of *M.*
229 *tuberculosis* infection, the finding could have implications as a diagnostic tool for
230 identification of individuals that are developing latent TB infection before any of the currently
231 available diagnostic methods. However, if the patterns we identified is not a result of bacterial
232 infection but rather an epigenomic dysregulation predisposing individuals to convert upon
233 exposure, this global DNA methylation pattern could have implications in identifying risk-
234 groups who are more prone to convert upon exposure.

235

236 We recognize that this study was performed on a small number of study subjects and further
237 investigation in larger cohorts is needed to elucidate the results presented here. We also
238 acknowledge the limitations of the study design, we included a cohort of study subjects with
239 risk of *M. tuberculosis* exposure, but no definite measurement of exposure. The observations
240 made with IGRA converters were limited to two study subjects. However, we highlight the
241 significance of investigating pulmonary immune cells and the value of investigating DNA
242 methylomes in the same study subjects, longitudinally, before and after IGRA conversion.

243 **Methods**

244 *Ethical Statement*

245 Ethical approval was obtained from Universidad Peruana Cayetano Heredia (UPCH)

246 Institutional Review Board N° 103793. All participants signed an informed consent.

247

248 *Study cohort and design*

249 This was a prospective study aimed to investigate epigenetic DNA methylome alterations in
250 pulmonary immune cells pre- and post- *M. tuberculosis* exposure in a natural setting. We
251 enrolled medical students ($n=15$) in the fifth or sixth year of medical school at UPCH. The
252 students donated sputum and blood samples before (0 months) and after (6 months) they had
253 clinical rotations in high-risk departments of *M. tuberculosis* exposure. The department of
254 infectious disease and internal medicine including the emergency department were defined as
255 departments with high-risk of *M. tuberculosis* exposure. Sputum was used to isolate immune
256 cells from the lung and the blood was used for IGRA. At inclusion, the participants filled in
257 an individual case report form with demographic information. Participants also filled in an
258 online questionnaire to collect background information before each session at 0 and 6 months.
259 The questionnaire was created in the tool Survey & Report, provided by Linköping
260 University. Samples from 10 individuals (collected at 0 and 6 months for IGRA_{neg} ($n=7$) and
261 IGRA converters ($n=2$) and at 0 months for IGRA_{pos} ($n=1$)) resulted in 19 samples that was
262 selected for each cell type (AMs and alveolar T cells), for the sequencing analysis. The
263 sample selection was based on results in the online questionnaire and on sample quality with
264 regards to DNA concentration in the obtained in both AMs and T cells at the two sample
265 collections at 0 and 6 months.

266

267 *Interferon gamma releasing assay with QuantiFERON® TB-Gold Plus*

268 At inclusion and follow-up, the participants donated blood samples that were used for IGRA
269 with the QuantiFERON® TB-Gold Plus test (SSI Diagnostica, Hillerød, Denmark) according
270 to the manufacturer's instructions. Tubes were filled and incubated at 37°C for maximum 24
271 hours and then analyzed with ELISA.

272

273 *Sputum Induction*

274 The sputum induction²³ was performed with an eFlow rapid nebulizer (PARI, Hamburg,
275 Germany) filled with a hypertonic saline solution. The solution was prepared by mixing
276 sterile water (Fresenius Kabi, Stockholm, Sweden) with 4% sodium chloride (B. Braun
277 Medical AB, Stockholm, Sweden). The participants inhaled the solution for 9 minutes while
278 simultaneously performing breathing exercises in accordance with instructions from the lung
279 clinic at Linköping University Hospital. The participants were asked to cough deeply to
280 expectorate sputum from the lungs. The expectorates were collected into sterile 50 ml Falcon
281 tubes (Thermo Fisher Scientific, Waltham, US) after each session. The Falcon tubes were
282 kept on ice. The sputum inductions were performed in three replicates.

283

284 *Sputum Processing and CD3 and HLA-DR Positive Cell Isolation*

285 From the sputum samples, within two hours, plugs containing pulmonary immune cells²³
286 were picked and pooled. The plugs were dissolved by adding 0.1% dithiothreitol (DTT)
287 (Thermo Fisher Scientific) mixed in phosphate-buffered saline (PBS) (Gibco, Cambridge,
288 UK). This was added in a volume approximately 4 times the collected sputum volume and
289 then vortexed and placed on a tilter with ice for 20 min. The dissolved sputum sample was
290 then filtered through 50 µm cell strainers (Sigma-Aldrich, Saint Louise, US) into a new 50 ml
291 Falcon tube and centrifuged for 5 min at 380g in 4°C. The supernatant was discarded, and the
292 pellet was resuspended in 500 µl of an isolation buffer containing 500 mM

293 ethylenediaminetetraacetic acid (EDTA), 0.1% fetal bovine serum (FBS), Ca²⁺ and Mg²⁺ free
294 PBS (pH 7.4). First, CD3 positive cells were isolated from the resuspended pellet. 25 µl of
295 Dynabeads CD3 (Invitrogen Dynabeads®, Life Technologies AS, Oslo, Norway) were
296 washed with 800 µl PBS and placed in a DynaMag-2 (Thermo Fisher Scientific) for 1 min.
297 The supernatant was discarded and 800 µl isolation buffer were added two times for
298 additional washing. The beads were then mixed with 500 µl of the cell sample and incubated
299 for 30 min at 4°C while tilting. After incubation, the tube was placed in the DynaMag-2,
300 supernatant was removed to be used to isolate HLA-DR positive cells next. The CD3 positive
301 cells were resuspended in 200 µl PBS.

302 Secondly, HLA-DR positive cells were isolated. 25 µl Magnetic Pan Mouse IgG
303 Dynabeads™ (cat no: 11041, Thermo Fisher) were washed with 800 µl PBS and placed in a
304 DynaMag-2 (Thermo Fisher Scientific) for 1 min. The supernatant was discarded and 800 µl
305 isolation buffer were added two times for additional washing. 5 µl monoclonal HLA-DR
306 antibodies (cat no: 14-9956-82, Thermo Fisher) were added to conjugate the Dynabeads.
307 Tubes were incubated for 40 min, then placed in the DynaMag-2 for 30 seconds and
308 supernatant removed. 800 µl isolation buffer were added two times for washing. The tube was
309 placed in DynaMag-2 for 30 seconds and supernatant removed. The beads were then mixed
310 with 500 µl of the supernatant from the CD3 isolation and incubated for 30 min at 4°C while
311 tilting. After incubation, the tube was placed in the DynaMag-2, supernatant was discarded,
312 and HLA-DR positive cells were resuspended in 200 µl PBS. CD3 positive cells are referred
313 to as alveolar T cells (T cells) and HLA-DR positive cells are referred to as alveolar
314 macrophages (AMs).

315

316 *DNA Extraction and Quantification*

317 DNA was extracted from the AMs and T cells with the AllPrep® DNA/RNA Mini Kit
318 (Qiagen, Hilden, Germany) within 4 hours from cell isolation. Concentration of DNA was
319 quantified with a Qubit® 4.0 Fluorometer (Thermo Fisher Scientific), using dsDNA High
320 Sensitivity (HS) Assay Kit (Thermo Fisher Scientific). The measurement was performed
321 according to the manufacturer's instructions.

322

323 *Reduced Representation Bisulfite Sequencing of DNA from AMs and T cells*

324 DNA samples were sequenced with Reduced Representation Bisulfide Sequencing (RRBS) at
325 the Bioinformatics and Expression Analysis (BEA) core facility at Karolinska Institute (KI)
326 with Diagenode's RRBS. The DNA was enzymatically digested, bisulfite converted, and PCR
327 amplified before ready for Illumina's HiSeq 2000. The use of the restriction enzyme MspI,
328 which cleaves CCGG from the 5' end, results in shorter sequences to analyze and is therefore
329 cost-effective.

330

331 *Data processing and computational analysis*

332 The RAW files (in fastq format) were generated from the RRBS analysis, were quality
333 checked using the fastQC ⁴⁷ (v0.11.9). The sequences were trimmed to remove artificially
334 filled-in cytosines at the 3' end using the TrimGalore (v.0.6.5) ⁴⁸ with a phred score cutoff of
335 20 and quality checked again after trimming. The trimmed sequences were aligned with the
336 human reference genome (hg38.13) using Bowtie2 ⁴⁹ and removed the deduplicates using the
337 Bismark v.0.22.3 ⁵⁰. The methylation extractor from Bismark was used to extract the CpG
338 methylation data from the sequences. The SAMtools (v1.7) ⁵¹ package was used to sort the
339 bam files on CpG-site chromosomal location and converted to SAM files. The methylated and
340 unmethylated CpG counts were extracted and combined using the DMRfinder (v0.3) ⁵²
341 package in R (v4.0.2) ⁵³.

342 To read the Bismark coverage files, the *edgeR* (v3.32.1)^{54,55} package was used. The CpG-
343 sites located in the X and Y chromosome as well as CpG-sites from mitochondrial DNA were
344 filtered out. CpG-sites with a read coverage < 5 with both methylated and unmethylated reads
345 were removed from the analysis. The M-values were calculated using the log₂ ratio of the
346 intensities of methylated versus unmethylated CpG-sites (with addition of +2 to each count to
347 avoid logarithms of zeros)⁵⁶.

$$348 \quad M_i = \log_2 \left(\frac{\max(y_{i,methylation}, 0) + \alpha}{\max(y_{i,unmethylation}, 0) + \alpha} \right), \alpha=2$$

349 The CpG-sites were annotated using *org.Hs.eg.db* (v3.12)⁵⁷ and *AnnotationDbi* (v1.52)⁵⁸
350 packages. After filtering and annotating the data, we identified a total of 1186 CpG-sites in
351 the AMs and 404 CpG-sites from T cells that were covered in all samples.

352

353 *Statistical analysis*

354 The Principal Component Analysis (PCA) was calculated using the *factoExtra* (v1.0.7)⁵⁹ and
355 *factoMineR* (v2.4)⁶⁰. The hierarchical clusters was estimated using the *ape* (v5.4-1)⁶¹ and
356 *dendextend* (v1.14.0)⁶² by calculating the Euclidian similarity/dissimilarity matrix. For the
357 identification of the individual differentially methylated CpG-sites (DMCs) the EdgeR *lmFit*
358 function⁶³ was used to estimate the counts of the unmethylated (Un) and methylated (Me)
359 reads in the conditions 0 months (A) and 6 months (B) in each individual, calculated as:

$$360 \quad \beta \wedge A = \log_2 \left(\frac{MeA + \alpha}{UnA + \alpha} \right), \alpha = 0.125$$

$$361 \quad \beta \wedge B = \log_2 \left(\frac{MeB + \alpha}{UnB + \alpha} \right), \alpha = 0.125$$

362 DMCs were defined as CpG-sites with a $|\log_2FC| > 5$ and significant with the Benjamini-
363 Hochberg (BH) corrected *p*-value < 0.01. The lollipop plots and the upset plots were made
364 using the *ggpubr* (v0.4.0)⁶⁴ and the *UpSetR* (v1.4.0)^{65,66} packages. Two IGRA_{neg} study
365 subjects and 1 study subject had no DMCs with a $|\log_2FC| > 15$ in the AMs and T cells

366 respectively and were therefore excluded from the analysis. The pathway analysis was
367 performed with the DMGs with a $|\log_2FC| > 15$ and Benjamini-Hochberg (BH) corrected p -
368 value < 0.01 unique to the IGRA converters AMs and T cells respectively from the
369 PANTHER database (v16.0)²⁶ using the WEB-based Gene SeT AnaLysis Toolkit
370 (WebGestalt) webserver (v2019)²⁵. The false discovery rate (FDR) in the pathway analysis is
371 BH corrected p -values. The significant pathways identified in the AMs and the top 4 most
372 significant pathways identified in the T cells are presented in Table 2.

373 **Data availability**

374 The datasets will be made available at the final publication.

375

376 **Acknowledgements**

377 We thank the Bioinformatics and Expression Analysis core facility (BEA) at Karolinska

378 Institute that preformed the sequencing analysis. We thank the Swedish National

379 Infrastructure for Computing (SNIC) at National Supercomputing Centre (NSC), Linköping

380 University for the computing systems enabling the data handling, partially funded by the

381 Swedish Research Council through grant agreement N° 2018-05973. The work was supported

382 by grants from the Swedish Research Council (Vetenskapsrådet) N° 2018-05973 and N° 2018-

383 04246 and the Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica

384 CONCYTEC and Cienciactiva N° 106-2018-FONDECYT. J.D is a postdoctoral fellow

385 supported through the Medical Infection and Inflammation Center (MIIC) at Linköping

386 University.

387

388 **Author Contributions**

389 N.I, J.P, I.P, C.U-G, M.M-A and M.L wrote the ethical application and conceived the study.

390 I.P, M.N and A.T performed all sample collections. J.D and L.K preformed the bioinformatic

391 analyses. M.L, L.K, J.D and I.P wrote the manuscript. M.M-A and C.U-G supervised the

392 project in Peru.

393

394 **Consent for publication**

395 All authors have approved the final version of the manuscript.

396

397 **Competing Interests**

398 The authors declare no competing interests.

399 **References**

- 400 1. World Health Organization. *Global Tuberculosis Report*.
401 <https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf>
402 (2019).
- 403 2. Schön, T., Lerm, M. & Stendahl, O. Shortening the ‘short-course’ therapy- insights into
404 host immunity may contribute to new treatment strategies for tuberculosis. *J. Intern.*
405 *Med.* **273**, 368–382 (2013).
- 406 3. Lerm, M. & Netea, M. G. Trained immunity: A new avenue for tuberculosis vaccine
407 development. *Journal of Internal Medicine* (2016) doi:10.1111/joim.12449.
- 408 4. Verrall, A. J. *et al.* Early clearance of Mycobacterium tuberculosis is associated with
409 increased innate immune responses . *J. Infect. Dis.* (2019) doi:10.1093/infdis/jiz147.
- 410 5. Verrall, A. J. *et al.* Early Clearance of Mycobacterium tuberculosis: The INFECT Case
411 Contact Cohort Study in Indonesia. *J. Infect. Dis.* (2019) doi:10.1093/infdis/jiz168.
- 412 6. Verrall, A. J., G. Netea, M., Alisjahbana, B., Hill, P. C. & van Crevel, R. Early
413 clearance of Mycobacterium tuberculosis: A new frontier in prevention. *Immunology*
414 (2014) doi:10.1111/imm.12223.
- 415 7. O’Garra, A. *et al.* The Immune Response in Tuberculosis. *Annu. Rev. Immunol.* (2013)
416 doi:10.1146/annurev-immunol-032712-095939.
- 417 8. Cooper, A. M. Cell-Mediated Immune Responses in Tuberculosis. *Annu. Rev.*
418 *Immunol.* **27**, 393–422 (2009).
- 419 9. Lerner, T. R., Borel, S. & Gutierrez, M. G. The innate immune response in human
420 tuberculosis. *Cellular Microbiology* (2015) doi:10.1111/cmi.12480.
- 421 10. Pieters, J. Mycobacterium tuberculosis and the Macrophage: Maintaining a Balance.
422 *Cell Host and Microbe* vol. 3 399–407 (2008).
- 423 11. Pai, M. *et al.* Gamma interferon release assays for detection of Mycobacterium

- 424 tuberculosis infection. *Clin. Microbiol. Rev.* (2014) doi:10.1128/CMR.00034-13.
- 425 12. LENDRUM, J. D. Tuberculin skin testing. *Med. World (New. York)*. (1953)
426 doi:10.1378/chest.76.6_supplement.764.
- 427 13. Netea, M. G. *et al.* Trained immunity: A program of innate immune memory in health
428 and disease. *Science* (2016) doi:10.1126/science.aaf1098.
- 429 14. Seeley, J. J. *et al.* Induction of innate immune memory via microRNA targeting of
430 chromatin remodelling factors. *Nature* (2018) doi:10.1038/s41586-018-0253-5.
- 431 15. Villota-Salazar, N. A., Mendoza-Mendoza, A. & González-Prieto, J. M. Epigenetics:
432 from the past to the present. *Front. Life Sci.* (2016)
433 doi:10.1080/21553769.2016.1249033.
- 434 16. Bock, C. *et al.* DNA Methylation Dynamics during In Vivo Differentiation of Blood
435 and Skin Stem Cells. *Mol. Cell* **47**, 633–647 (2012).
- 436 17. Verma, D. *et al.* Anti-mycobacterial activity correlates with altered DNA methylation
437 pattern in immune cells from BCG-vaccinated subjects. *Sci. Rep.* **7**, 1–10 (2017).
- 438 18. Hasso-Agopsowicz, M., Scriba, T. J., Hanekom, W. A., Dockrell, H. M. & Smith, S. G.
439 Differential DNA methylation of potassium channel KCa3.1 and immune signalling
440 pathways is associated with infant immune responses following BCG vaccination. *Sci.*
441 *Rep.* (2018) doi:10.1038/s41598-018-31537-9.
- 442 19. Das, J., Verma, D., Gustafsson, M. & Lerm, M. Identification of DNA methylation
443 patterns predisposing for an efficient response to BCG vaccination in healthy BCG-
444 naïve subjects. *Epigenetics* **14**, 589–601 (2019).
- 445 20. Yona, S., Viukov, S., Guilliams, M. & Misharin, A. Tissue Macrophages Under
446 Homeostasis. *Immunity* **38**, 79–91 (2013).
- 447 21. Yao, Y. *et al.* Induction of Autonomous Memory Alveolar Macrophages Requires T
448 Cell Help and Is Critical to Trained Immunity. *Cell* (2018)

- 449 doi:10.1016/j.cell.2018.09.042.
- 450 22. Pérez-Lu, J. E., Cárcamo, C. P., García, P. J., Bussalleu, A. & Bernabé-Ortiz, A.
451 Tuberculin skin test conversion among health sciences students: A retrospective cohort
452 study. *Tuberculosis* (2013) doi:10.1016/j.tube.2012.10.001.
- 453 23. Das, J., Idh, N., Sikkeland, L. I. B., Paues, J. & Lerm, M. DNA methylome-based
454 validation of induced sputum as an effective protocol to study lung immunity:
455 construction of a classifier of pulmonary cell types. *bioRxiv* (2021)
456 doi:10.1101/2021.03.12.435086.
- 457 24. Jonsson, J. *et al.* A borderline range for Quantiferon Gold In-Tube results. *PLoS One*
458 (2017) doi:10.1371/journal.pone.0187313.
- 459 25. Liao, Y., Wang, J., Jaehnig, E. J., Shi, Z. & Zhang, B. WebGestalt 2019: gene set
460 analysis toolkit with revamped UIs and APIs. *Nucleic Acids Res.* (2019)
461 doi:10.1093/nar/gkz401.
- 462 26. Thomas, P. D. *et al.* PANTHER: A library of protein families and subfamilies indexed
463 by function. *Genome Res.* (2003) doi:10.1101/gr.772403.
- 464 27. Wei, M. *et al.* NLRP3 Activation Was Regulated by DNA Methylation Modification
465 during Mycobacterium tuberculosis Infection. *Biomed Res. Int.* (2016)
466 doi:10.1155/2016/4323281.
- 467 28. Sharma, G. *et al.* Genome-wide non-CpG methylation of the host genome during M.
468 tuberculosis infection. *Sci. Rep.* (2016) doi:10.1038/srep25006.
- 469 29. Zheng, L. *et al.* Unraveling methylation changes of host macrophages in
470 Mycobacterium tuberculosis infection. *Tuberculosis* (2016)
471 doi:10.1016/j.tube.2016.03.003.
- 472 30. DiNardo, A. R. *et al.* DNA hypermethylation during tuberculosis dampens host
473 immune responsiveness. *J. Clin. Invest.* (2020) doi:10.1172/JCI134622.

- 474 31. Cadena, A. M., Fortune, S. M. & Flynn, J. L. Heterogeneity in tuberculosis. *Nature*
475 *Reviews Immunology* (2017) doi:10.1038/nri.2017.69.
- 476 32. Sharma, G., Upadhyay, S., Srilalitha, M., Nandicoori, V. K. & Khosla, S. The
477 interaction of mycobacterial protein Rv2966c with host chromatin is mediated through
478 non-CpG methylation and histone H3/H4 binding. *Nucleic Acids Res.* (2015)
479 doi:10.1093/nar/gkv261.
- 480 33. Yaseen, I., Kaur, P., Nandicoori, V. K. & Khosla, S. Mycobacteria modulate host
481 epigenetic machinery by Rv1988 methylation of a non-tail arginine of histone H3. *Nat.*
482 *Commun.* (2015) doi:10.1038/ncomms9922.
- 483 34. Kumar, R. *et al.* Immunometabolism of Phagocytes During Mycobacterium
484 tuberculosis Infection. *Frontiers in Molecular Biosciences* (2019)
485 doi:10.3389/fmolb.2019.00105.
- 486 35. Cumming, B. M., Addicott, K. W., Adamson, J. H. & Steyn, A. J. C. Mycobacterium
487 tuberculosis induces decelerated bioenergetic metabolism in human macrophages. *Elife*
488 (2018) doi:10.7554/eLife.39169.
- 489 36. Giri, P. K., Kruh, N. A., Dobos, K. M. & Schorey, J. S. Proteomic analysis identifies
490 highly antigenic proteins in exosomes from M. tuberculosis-infected and culture filtrate
491 protein-treated macrophages. *Proteomics* (2010) doi:10.1002/pmic.200900840.
- 492 37. Sanders, V. M. *et al.* Differential expression of the beta2-adrenergic receptor by Th1
493 and Th2 clones: implications for cytokine production and B cell help. *J. Immunol.*
494 (1997).
- 495 38. Borger, P. *et al.* β -Adrenoceptor-mediated inhibition of IFN- γ , IL-3, and GM-CSF
496 mRNA accumulation in activated human T lymphocytes is solely mediated by the β 2-
497 Adrenoceptor subtype. *Am. J. Respir. Cell Mol. Biol.* (1998)
498 doi:10.1165/ajrcmb.19.3.2765.

- 499 39. Estrada, L. D., Ağaç, D. & Farrar, J. D. Sympathetic neural signaling via the β 2-
500 adrenergic receptor suppresses T-cell receptor-mediated human and mouse CD8+ T-
501 cell effector function. *Eur. J. Immunol.* (2016) doi:10.1002/eji.201646395.
- 502 40. Swanson, M. A., Lee, W. T. & Sanders, V. M. IFN- γ Production by Th1 Cells
503 Generated from Naive CD4 + T Cells Exposed to Norepinephrine . *J. Immunol.* (2001)
504 doi:10.4049/jimmunol.166.1.232.
- 505 41. Azar, A. F., Jazani, N. H., Bazmani, A., Vahhabi, A. & Shahabi, S. Polymorphisms in
506 Beta-2 Adrenergic Receptor Gene and Association with Tuberculosis. *Lung* (2017)
507 doi:10.1007/s00408-016-9968-y.
- 508 42. Fujii, T. *et al.* Expression and function of the cholinergic system in immune cells.
509 *Frontiers in Immunology* (2017) doi:10.3389/fimmu.2017.01085.
- 510 43. Murray, K. *et al.* Neuroanatomy of the spleen: Mapping the relationship between
511 sympathetic neurons and lymphocytes. *PLoS One* (2017)
512 doi:10.1371/journal.pone.0182416.
- 513 44. Cox, M. A. *et al.* Choline acetyltransferase-expressing T cells are required to control
514 chronic viral infection. *Science* (80-.). (2019) doi:10.1126/science.aau9072.
- 515 45. Pollock, N. R. *et al.* Evaluation of the Effect of Treatment of Latent Tuberculosis
516 Infection on QuantiFERON-TB Gold Assay Results. *Infect. Control Hosp. Epidemiol.*
517 (2009) doi:10.1086/596606.
- 518 46. Dyrhol-Riise, A. M. *et al.* Diagnosis and follow-up of treatment of latent tuberculosis;
519 the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a
520 tuberculosis low-endemic country. *BMC Infect. Dis.* (2010) doi:10.1186/1471-2334-10-
521 57.
- 522 47. Andrews, S. FASTQC A Quality Control tool for High Throughput Sequence Data.
523 *Babraham Inst.* (2015).

- 524 48. Krueger, F. Trim Galore: a wrapper tool around gutadapt and FastQC to consistently
525 apply quality and adapter trimming to FastQ files. Available from
526 <https://www.bioinformatics.babraham.ac.uk/projects>. *Babraham Institute* (2015).
- 527 49. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat.*
528 *Methods* (2012) doi:10.1038/nmeth.1923.
- 529 50. Krueger, F. & Andrews, S. R. Bismark: A flexible aligner and methylation caller for
530 Bisulfite-Seq applications. *Bioinformatics* (2011) doi:10.1093/bioinformatics/btr167.
- 531 51. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics*
532 (2009) doi:10.1093/bioinformatics/btp352.
- 533 52. Gaspar, J. M. & Hart, R. P. DMRfinder: Efficiently identifying differentially
534 methylated regions from MethylC-seq data. *BMC Bioinformatics* (2017)
535 doi:10.1186/s12859-017-1909-0.
- 536 53. Rstudio, T. RStudio: Integrated Development for R. *Rstudio Team, PBC, Boston, MA*
537 *URL* <http://www.rstudio.com/> (2020) doi:10.1145/3132847.3132886.
- 538 54. Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: A Bioconductor package for
539 differential expression analysis of digital gene expression data. *Bioinformatics* (2009)
540 doi:10.1093/bioinformatics/btp616.
- 541 55. McCarthy, D. J., Chen, Y. & Smyth, G. K. Differential expression analysis of
542 multifactor RNA-Seq experiments with respect to biological variation. *Nucleic Acids*
543 *Res.* (2012) doi:10.1093/nar/gks042.
- 544 56. Du, P. *et al.* Comparison of Beta-value and M-value methods for quantifying
545 methylation levels by microarray analysis. *BMC Bioinformatics* (2010)
546 doi:10.1186/1471-2105-11-587.
- 547 57. Marc Carlson. org.Mm.eg.db: Genome wide annotation for Mouse. R package version
548 3.8.2. *Bioconductor* (2019).

- 549 58. Pagès, H., Carlson, M., Falcon, S. & Maintainer, N. L. Package ‘AnnotationDbi’.
550 *Bioconductor Packag. Maint.* (2017).
- 551 59. Kassambara, A. & Mundt, F. factoextra: Extract and Visualize the Results of
552 Multivariate Data Analyses. Package Version 1.0.7. *R Packag. version* (2020).
- 553 60. Lê, S., Josse, J. & Husson, F. FactoMineR: An R package for multivariate analysis. *J.*
554 *Stat. Softw.* (2008) doi:10.18637/jss.v025.i01.
- 555 61. Paradis, E. & Schliep, K. Ape 5.0: An environment for modern phylogenetics and
556 evolutionary analyses in R. *Bioinformatics* (2019) doi:10.1093/bioinformatics/bty633.
- 557 62. Galili, T. dendextend: An R package for visualizing, adjusting and comparing trees of
558 hierarchical clustering. *Bioinformatics* (2015) doi:10.1093/bioinformatics/btv428.
- 559 63. Smyth, G. K., Chen, Y., Pal, B. & Visvader, J. E. Differential methylation analysis of
560 reduced representation bisulfite sequencing experiments using edgeR. *F1000Research*
561 (2017) doi:10.12688/f1000research.13196.1.
- 562 64. Kassambara, A. Package ‘ggpubr’: ‘ggplot2’ Based Publication Ready Plots. *R Packag.*
563 *version 0.4.0* (2020).
- 564 65. Lex, A., Gehlenborg, N., Strobel, H., Vuillemot, R. & Pfister, H. UpSet: Visualization
565 of intersecting sets. *IEEE Trans. Vis. Comput. Graph.* (2014)
566 doi:10.1109/TVCG.2014.2346248.
- 567 66. Conway, J. R., Lex, A. & Gehlenborg, N. UpSetR: An R package for the visualization
568 of intersecting sets and their properties. *Bioinformatics* (2017)
569 doi:10.1093/bioinformatics/btx364.
- 570

571 **Figure and Table legends**

572 **Figure 1. Flow chart of the study design.** Study subjects donated sputum and blood samples
573 at 0 and 6 months, which corresponded to before and after clinical rotations at departments
574 with high-risk of *M. tuberculosis* exposure at hospitals in Lima, Peru. IGRA tests were taken
575 to confirm TB-infection. AMs and alveolar T cells were isolated from sputum samples. DNA
576 was extracted and the samples were sequenced with reduced representation bisulfite
577 sequencing (RRBS) for methylation analysis.

578

579 **Figure 2. Unique distribution of genomic DNA methylation discriminates IGRA-**
580 **converting individuals.** Density plots of the distribution of M-values from CpG-sites
581 identified in **A.** AMs and **B.** alveolar T cells. Full line represents samples collected at 0
582 months and dotted lines samples collected at 6 months. The Principal Component Analysis
583 (PCA) of the methylation data from **C.** AMs and **D.** alveolar T cells. The ellipses represent the
584 70% confidence interval (C.I.) in the dataset.

585

586 **Figure 3. Hierarchical clustering analysis separating IGRA-converting individuals. A,B.**
587 Unsupervised hierarchical clustering dendrogram applying the Euclidian distance matrix
588 calculation and Ward D2 method. The dendrograms show the clustering of methylome data
589 from **A.** AMs. and **B.** alveolar T cells. The scale represents the Euclidean distance.

590

591 **Figure 4. Heatmaps reveal a different overall DNA methylation pattern in IGRA-**
592 **converting study subjects. A.** Heatmap of all CpG-sites (1186) identified in the AMs of each
593 study subject. **B.** Heatmap of all CpG-sites (404) identified from the alveolar T cells. The
594 color bar represents the M-value scale ranging from -10 (blue) to 10 (red).

595

596 **Figure 5. Profound DNA methylome alterations identified in IGRA-converting study**
597 **subjects.** Lollipop plots showing the number of differentially methylated CpG-sites (DMCs)
598 identified in the **A.** AMs and **B.** alveolar T cells of each study subject. **C.** The percentage of
599 DMCs with a $|\log_2FC| > 15$ compared to the total number of DMCs ($|\log_2FC| > 5$, adj p -value
600 > 0.01) identified in each study subject AMs and T cells.

601

602 **Figure 6. IGRA converters undergo unique DNA methylation changes during IGRA**
603 **conversion.** UpSet plot showing the intersects of the DMGs identified in each study subjects
604 AMs.

605

606 **Figure S1. UpSet plot showing the intersects of the DMGs identified in each study**
607 **subject's alveolar T cells.** UpSet plot showing the intersects of the DMGs identified in each
608 study subjects T cells.

609

610

611 Table 1. **Demographics of study subjects.** A total of 15 participants were included in the
612 study. IGRA test confirmed IGRA conversion in two study subjects. [□] shows the range of the
613 data.

| Characteristics | Participants (N=15) |
|--|-------------------------------|
| Sex (male and female) | 8 / 7 |
| Age (years) | 22.7 (21-29) [□] |
| Weight (kg) | 70.5 (48.5-101) [□] |
| Height (cm) | 168.8 (159-182) [□] |
| BMI (kg/m ²) | 24.6 (17.2-34.5) [□] |
| IGRA result 0 months (negative and positive) | 14 / 1 |
| IGRA result 6 months (negative and positive) | 12 / 3 |

614

615

616 Table 2. **ORA of DMG intersect from IGRA converter's AMs**

617 ORA using Panther pathways of the DMG intersect identified in the AMs of the IGRA
618 converters.

| Gene Set | Description | Ratio | p-value | FDR |
|-----------------|---------------------------|--------------|----------------|------------|
| P02762 | Pentose Phosphate Pathway | 20.981 | 0.004 | 0.41 |
| P04393 | Ras Pathway | 3.596 | 0.049 | 1 |

619

620

621 Table 3. **ORA of DMG intersect from IGRA converter's alveolar T cells**

622 ORA of the DMG intersect identified in the T cells of the IGRA converters.

| Gene Set | Description | Ratio | p-value | FDR |
|-----------------|--------------------|--------------|----------------|------------|
|-----------------|--------------------|--------------|----------------|------------|

| | | | | |
|--------|---|------|-------|------|
| P00042 | Muscarinic acetylcholine receptor 1 and 3 signaling pathway | 6.34 | 0.003 | 0.35 |
| P04377 | Beta 1 adrenergic receptor signaling pathway | 6.08 | 0.012 | 0.44 |
| P04378 | Beta 2 adrenergic receptor signaling pathway | 6.08 | 0.012 | 0.44 |
| P00043 | Muscarinic acetylcholine receptor 2 and 4 signaling pathway | 4.8 | 0.022 | 0.44 |

623

Figure 1




Figure 2








Figure 3

A



B





Figure 4

A



B






Figure 5

A



B



C




Figure 6

medRxiv preprint doi: <https://doi.org/10.1101/2021.03.16.21253729>; this version posted March 20, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

